Search

Your search keyword '"Politi, K"' showing total 190 results

Search Constraints

Start Over You searched for: Author "Politi, K" Remove constraint Author: "Politi, K"
190 results on '"Politi, K"'

Search Results

1. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

2. DOK2 inhibits EGFR-mutated lung adenocarcinoma

6. Contributors

9. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

11. Deconstructing tumor heterogeneity : The stromal perspective

12. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

13. Correction to: Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop (Journal for ImmunoTherapy of Cancer (2020) 7 (131) DOI: 10.1186/s40425-019-0602-4)

15. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

16. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

17. P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor

18. OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

19. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab

20. Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA

24. Oncogenes Come of Age

25. Retinoic acid down-regulation of fibronectin and retinoic acid receptor alpha proteins in NIH-3T3 cells. Blocks of this response by ras transformation.

28. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.

29. OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation.

30. Utility of Electroencephalograms for Enhancing Clinical Care and Rehabilitation of Children with Acquired Brain Injury.

31. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.

33. Xanthogranulomatous Pyelonephritis: A pooled quantitative analysis of published cases.

34. Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment.

35. The Evolution of Mouse Models of Cancer: Past, Present, and Future.

36. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

37. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma.

38. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.

39. EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth.

40. The New NCI Precision Medicine Trials.

41. Oncogenic context shapes the fitness landscape of tumor suppression.

42. Effect of Dietary Supplementation with a Mixture of Natural Antioxidants on Milk Yield, Composition, Oxidation Stability and Udder Health in Dairy Ewes.

43. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

44. Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.

45. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.

46. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy.

47. An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.

48. EGFR + lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth.

49. Challenges and opportunities for modeling aging and cancer.

50. Overexpressed Malat1 Drives Metastasis through Inflammatory Reprogramming of Lung Adenocarcinoma Microenvironment.

Catalog

Books, media, physical & digital resources